Pancreatic safety of sitagliptin in the TECOS Study.

Pancreatic safety of sitagliptin in the TECOS Study.

<h4>Objective</h4> <p>We evaluated the incidence of acute pancreatitis and pancreatic cancer in patients with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i).</p> <h4>Research Design and Methods</h4>...

Full description

Bibliographic Details
Main Authors:	Buse, J, Bethel, M, Green, J, Stevens, S, Lokhnygina, Y, Aschner, P, Grado, C, Tankova, T, Wainstein, J, Josse, R, Lachin, J, Engel, S, Patel, K, Peterson, E, Holman, R, TECOS Study Group
Format:	Journal article
Language:	English
Published:	American Diabetes Association 2016

Similar Items

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: Outcomes from TECOS.
by: Engel, S, et al.
Published: (2017)

Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
by: Bethel, M, et al.
Published: (2017)

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS Trial.
by: Josse, R, et al.
Published: (2016)

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
by: Bethel, M, et al.
Published: (2009)

Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: Outcomes from TECOS.
by: Cornel, J, et al.
Published: (2016)

Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
by: Reed, S, et al.
Published: (2018)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease
by: Green, J, et al.
Published: (2013)

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
by: Green, J, et al.
Published: (2013)

Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS
by: Michael A. Nauck, et al.
Published: (2019-09-01)

Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial
by: McGuire, D, et al.
Published: (2016)

PDP-6 TECO
by: Samson, Peter
Published: (2004)

An Input Macro for TECO
by: Eastlake, D.
Published: (2004)

Correspondence on sitagliptin and cardiovascular outcomes in type 2 diabetes
by: Holman, R, et al.
Published: (2015)

An experimental investigation of the efficiency of "Teco Rings" in transmitting stress
by: Bates, William J., 1811?-, et al.
Published: (2024)

Producing Memos, Using TJ6, TECO and the Type 37 Teletype
by: Krakauer, Lawrence J.
Published: (2004)

Sitagliptin and cardiovascular outcomes in type 2 diabetes - author's reply
by: Holman, RR, et al.
Published: (2015)

Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin
by: Zinman, B, et al.
Published: (2011)

Asymmetric synthesis of (-)-(R)-sitagliptin
by: Davies, S, et al.
Published: (2012)

Asymmetric synthesis of (-)-(R)-sitagliptin
by: Davies, S, et al.
Published: (2012)

Asymmetric synthesis of (-)-(R)-sitagliptin
by: Davies, S, et al.
Published: (2012)

Educational and training organizations management. Requirements to design assessment tasks in the frame of TECO-D research
by: Matteo Cornacchia, et al.
Published: (2018-12-01)

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
by: Mariko Sue, et al.
Published: (2013-02-01)

A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin
by: Mariko Sue, et al.
Published: (2013-01-01)

Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01)

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
by: Engel Samuel S, et al.
Published: (2013-01-01)

Rhinorrhea, cough and fatigue in patients taking sitagliptin
by: Baraniuk James N, et al.
Published: (2010-05-01)

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?
by: Yong Kyun Cho
Published: (2018-09-01)

Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin
Published: (2021-01-01)

Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin
by: Steinberg H, et al.
Published: (2013-05-01)

Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease
by: M. Angelyn Bethel, et al.
Published: (2023-03-01)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
by: Saba Sayari, et al.
Published: (2018-09-01)

Genome-Wide Transcriptome Analysis in Type 2 Diabetes Patients Treated by Sitagliptin
by: Ma R, et al.
Published: (2022-06-01)

Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor.
by: Felicia Goldsmith, et al.
Published: (2015-01-01)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
by: Shannon A Miller, et al.
Published: (2009-05-01)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
by: Timothy M. E. Davis, et al.
Published: (2022-06-01)

Sitagliptin Induces Tolerogenic Human Dendritic Cells
by: Marija Drakul, et al.
Published: (2023-11-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

Stability of extemporaneously prepared sitagliptin phosphate solution.
by: Abdel Naser Zaid, et al.
Published: (2022-01-01)

Stability of extemporaneously prepared sitagliptin phosphate solution
by: Abdel Naser Zaid, et al.
Published: (2022-01-01)

Practical Asymmetric Synthesis of Sitagliptin Phosphate Monohydrate
by: Haoling Gao, et al.
Published: (2018-06-01)